Eliem Therapeutics, Inc. (ELYM) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Redmond, WA, 美国. 现任CEO为 Aoife M. Brennan BAO, BCh, MB, MMSc.
ELYM 拥有 IPO日期为 2021-08-10, 9 名全职员工, 在 NASDAQ Global Market, 市值为 $342.68M.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
